S. Swann

6.2k total citations
33 papers, 696 citations indexed

About

S. Swann is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, S. Swann has authored 33 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in S. Swann's work include Lung Cancer Diagnosis and Treatment (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Melanoma and MAPK Pathways (8 papers). S. Swann is often cited by papers focused on Lung Cancer Diagnosis and Treatment (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Melanoma and MAPK Pathways (8 papers). S. Swann collaborates with scholars based in United States, United Kingdom and Australia. S. Swann's co-authors include Dilip Rajagopalan, Howard Ball, Lini Pandite, Catherine L. Carpenter, Rafael G. Amado, Ying Lin, Mathiéu Molimard, Thomas E. Hutson, A. Benjamin Suttle and Robert Timmerman and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

S. Swann

33 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Swann United States 13 359 315 229 125 105 33 696
William B. Fisher United States 17 846 2.4× 760 2.4× 212 0.9× 82 0.7× 86 0.8× 39 1.2k
Kian Fong Foo Singapore 13 238 0.7× 320 1.0× 141 0.6× 27 0.2× 47 0.4× 24 712
Chun‐Ru Chien Taiwan 17 498 1.4× 408 1.3× 64 0.3× 105 0.8× 222 2.1× 58 1.0k
Libor Havel Czechia 21 980 2.7× 1.2k 3.9× 249 1.1× 83 0.7× 81 0.8× 54 1.6k
Laura L. Fernandes United States 10 149 0.4× 369 1.2× 63 0.3× 46 0.4× 37 0.4× 39 632
Evan C. Osmundson United States 14 181 0.5× 222 0.7× 207 0.9× 101 0.8× 83 0.8× 43 651
Astrid Dalhaug Norway 16 435 1.2× 386 1.2× 51 0.2× 68 0.5× 80 0.8× 70 715
David Gandara United States 9 547 1.5× 388 1.2× 126 0.6× 19 0.2× 73 0.7× 17 790
Béatrice Fournier Belgium 9 533 1.5× 387 1.2× 114 0.5× 124 1.0× 237 2.3× 22 913
Linda Coate Ireland 13 343 1.0× 333 1.1× 161 0.7× 16 0.1× 105 1.0× 36 756

Countries citing papers authored by S. Swann

Since Specialization
Citations

This map shows the geographic impact of S. Swann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Swann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Swann more than expected).

Fields of papers citing papers by S. Swann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Swann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Swann. The network helps show where S. Swann may publish in the future.

Co-authorship network of co-authors of S. Swann

This figure shows the co-authorship network connecting the top 25 collaborators of S. Swann. A scholar is included among the top collaborators of S. Swann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Swann. S. Swann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ascierto, Paolo A., Petr Arenberger, Victoria Atkinson, et al.. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. Annals of Oncology. 29. viii466–viii466. 1 indexed citations
2.
Diab, Adi, Cara Haymaker, Marc Uemura, et al.. (2017). A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. Annals of Oncology. 28. v421–v421. 11 indexed citations
3.
Latimer, Nicholas, et al.. (2015). Adjusting For Treatment Switching in Rcts – Identifying, Analysing and Justifying Appropriate Methods: a Case Study in Metastatic Melanoma. Value in Health. 18(7). A338–A338. 2 indexed citations
4.
Grob, Jean‐Jacques, Mayur M. Amonkar, Salvador Martín‐Algarra, et al.. (2014). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology. 25(7). 1428–1436. 37 indexed citations
5.
Suttle, A. Benjamin, Howard Ball, Mathiéu Molimard, et al.. (2014). Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. British Journal of Cancer. 111(10). 1909–1916. 147 indexed citations
6.
Menzies, Alexander M., Michelle T. Ashworth, S. Swann, et al.. (2014). Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Annals of Oncology. 26(2). 415–421. 64 indexed citations
7.
8.
Kulkarni, Diptee, Judong Shen, Linda P. Briley, et al.. (2014). Pharmacogenetic investigation of dabrafenib efficacy in a meta-analysis of three melanoma studies.. Journal of Clinical Oncology. 32(15_suppl). e20018–e20018. 1 indexed citations
9.
Shapiro, Geoffrey I., Stewart W. McCallum, Laurel M. Adams, et al.. (2012). A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Investigational New Drugs. 31(3). 742–750. 38 indexed citations
10.
Sarna, Linda, S. Swann, Corey J. Langer, et al.. (2008). Clinically Meaningful Differences in Patient-Reported Outcomes With Amifostine in Combination With Chemoradiation for Locally Advanced Non–Small-Cell Lung Cancer: An Analysis of RTOG 9801. International Journal of Radiation Oncology*Biology*Physics. 72(5). 1378–1384. 34 indexed citations
11.
12.
Nikolinakos, Petros, Nasser K. Altorki, Michael J. Guarino, et al.. (2008). Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. Journal of Clinical Oncology. 26(15_suppl). 7568–7568. 15 indexed citations
13.
Siddiqui, Farzan, R. Kohl, S. Swann, Deborah Watkins Bruner, & Benjamin Movsas. (2008). Gender differences in pretreatment quality of life in a prospective lung cancer trial.. PubMed. 6(1). 33–9. 10 indexed citations
14.
Ryu, Janice, S. Swann, Francis G. LeVeque, et al.. (2007). The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: A double-blind placebo-controlled prospective Phase III study by Radiation Therapy Oncology Group 9901. International Journal of Radiation Oncology*Biology*Physics. 67(3). 643–650. 50 indexed citations
15.
Timmerman, Robert, James M. Galvin, Jeff M. Michalski, et al.. (2006). Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncologica. 45(7). 779–786. 98 indexed citations
16.
Soares, Heloisa P., Ambuj Kumar, S. Swann, et al.. (2005). Evaluation of New Treatments in Radiation Oncology. JAMA. 293(8). 970–970. 57 indexed citations
17.
18.
19.
Komaki, Ritsuko, S. Swann, Walter J. Curran, et al.. (2005). A Phase II Study of Cetuximab (C225) in Combination with Chemoradiation (CRT) in Patients (PTS) with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): An Interim Overall Toxicity Report of the RTOG 0324 Trial. International Journal of Radiation Oncology*Biology*Physics. 63. S44–S44. 5 indexed citations
20.
McDermott, Suzanne, et al.. (2002). Consultation in paediatric rehabilitation for behaviour problems in young children with cerebral palsy and/or developmental delay. Pediatric Rehabilitation. 5(2). 99–106. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William B. Fisher Breakdown of academic impact, for papers by Kian Fong Foo Breakdown of academic impact, for papers by Chun‐Ru Chien Breakdown of academic impact, for papers by Libor Havel Breakdown of academic impact, for papers by Laura L. Fernandes Breakdown of academic impact, for papers by Evan C. Osmundson Breakdown of academic impact, for papers by Astrid Dalhaug Breakdown of academic impact, for papers by David Gandara Breakdown of academic impact, for papers by Béatrice Fournier Breakdown of academic impact, for papers by Linda Coate
Rankless by CCL
2026